The Future of RNA Therapeutics is Modular

Among many exciting precision medicine strategies, RNA-based therapeutics are  rapidly growing in popularity and effectiveness. Although progress has been achieved  in developing RNA-targeted delivery carriers (mainly by using monoclonal antibodies for targeting), their clinical translation has yet to be fully recognized. This is due, in no small part, to massive development and production requirements and high batch-to-batch variability of current technologies, which currently rely on chemical conjugation. Novel synthesis methodologies could help vault these therapeutic strategies into the market and patients much more quickly.